Ann: Harvest One Operational Update, page-33

Links to the trials -

PTL101 (Phase 2) - https://clinicaltrials.gov/ct2/show/NCT02987114
PTL201 (Phase 2) - https://clinicaltrials.gov/show/NCT03005119

And here's the results announcement for Phase 1 (3/3/17) - http://clients3.weblink.com.au/clients/phytotech/headline.aspx?headlineid=6755047

"The Phase 1 clinical study assessed the safety and performance of the Gelpell CBD pills in two doses:
10mg CBD in comparison to the GW Pharmaceuticals oromucosal spray–Sativex; and a high dose of 100mg CBD to cover future indications requiring high doses.

The results of the Trials are extremely positive with consistent results among all 14 completers (14/15 initiating test subjects).

The Trial yielded the following promising results of the Gelpell CBD pills;
-Demonstrable safety and tolerability profile with no significant side effects;
-Higher bioavailability of the Gelpell CBD 10 in comparison to Sativex;
-Dose proportionality between Gelpell CBD 10mg to CBD 100mg; and
-24 hours exposure time in the plasma for the CBD 100mg."